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ABSTRACT 
Background: Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and 
mortality especially in lower and middle income countries (LMICs) such as India. Medicine costs are a 
key issue in LMICs with typically high patient co-payments. In addition, pharmacists are underutilised 
in LMICs including India. However, pharmacist-led educational interventions may improve the care of 
patients with COPD as well as reduce medicine costs. Consequently, the objective of this study was 
to assess the effectiveness of a pharmacist led intervention in reducing medicine costs. Methodology: 
We assessed the impact of a pharmacist intervention on direct medicine costs in COPD patients 
(medicine costs and pharmacist time) in a randomized controlled study involving an intervention and 
control group and conducted at a tertiary care teaching hospital in India. Results: The six-monthly cost 
of medicines at baseline increased with disease severity from a maximum of US$29.46 for those with 
mild COPD up to US$63.28 for those with very severe COPD. Substantial savings in medical costs 
were achieved with the pharmacist-led programme, up to a maximum of US$20.49 over six-months 
for very severe patients. This equates to a reduction of 30.6% in medicine costs (P < 0.001), reduced 
to 26.1% when pharmacists’ time (US$3.00/ patient) is included. Conclusion: There could be a key 
role for pharmacists as educators in COPD patients in LMICs to improve care and reduce costs 
including patient co-payments. 
 
Key points for decision makers 
 
* Chronic obstructive pulmonary disease is the 4th leading cause of death globally. Moreover, 90% of 
COPD-related deaths typically occur in low and middle income countries (LMICs) including India. 
* In India, medicine costs currently represent a major proportion of the total healthcare costs 
(approximately 38%). Consequently, there is a need to address this especially if most medicine costs 
are out-of-pocket 
* A clinical pharmacist-led intervention reduced the costs of medicines for patients with COPD by up 
to 30.6% whilst improving medication adherence and health related quality of life, with savings 
marginally lower once the costs of pharmacy time are included 
* This intervention is feasible and pragmatic and could potentially be implemented across India and in 
other LMICs given concerns with the paucity of physicians, availability of pharmacists and costs 
savings as India and other LMICs moves towards universal access 
 
1. Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterised 
by airflow limitation and obstruction (1, 2). COPD though is not fully reversible (unlike asthma) and is 
usually progressive (1). However, early diagnosis and treatment, including smoking cessation, 
reduces the rate of decline in lung function and is seen as beneficial (3, 4).  
 
Interest in COPD has grown in recent years across countries  including India with an estimated global 
prevalence of 210 million people and rising, with prevalence rates in India averaging 4.2%, ranging 
from 1% to 10% or higher depending on the State (2, 5-9). This is because COPD is a major cause of 
morbidity and mortality (2, 6, 10, 11). Currently, COPD is the fourth leading cause of death globally 
and likely to become the third leading cause by 2020 (4, 10, 12). 90% of COPD-related deaths 
typically occur in low and middle income countries (LMICs), with India and China accounting for two 
thirds of these (2, 13). Currently in India, chronic respiratory diseases are the third highest cause of 
mortality accounting for 11% of all deaths (6, 14), with COPD the greatest contributor at 8.7% of all 
deaths resulting in over 400,000 deaths a year (6, 8). As a result, deaths due to COPD in India are 
over four times higher than that seen among developed countries (10, 15). Lower socioeconomic 
status, including poor nutrition and childhood poverty, limited education and health literacy, as well as 
higher exposure to particulate matter in the air, are major causes of increased mortality due to COPD 
in LMICs such as India (16-21). Murthy et al in 2005 reported that incidence of COPD is higher in rural 
versus urban India, with lower socioeconomic status being one of the major factors (22). 
 
Of the total global disability life years (DALYs) due to chronic respiratory diseases, 32.0% of these 
currently occur in India (6), with COPD in India currently accounting for 4·8% of total worldwide 
DALYs (6). COPD is also associated with considerable economic burden, which is increasing (23-27). 
In the US in 2010, the projected annual cost of COPD was $49.9 billion including $29.5 billion of direct 
medical costs (24). In China, current annual direct medical costs for COPD are US$30.30billion, direct 
non-medical costs are US$1.36billion and indirect costs are US$5.28billion, with hospitalisations 
accounting for 56.7% of total costs (25).  In Korea, the estimated costs for COPD in 2018 were 
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approximately US$1.245 billion, with direct medical costs accounting for approximately 20% of this 
(23). In Germany, the annual excess cost of COPD in 2012 per patient compared with healthy 
subjects varied on average from €2,595 for Gold Grade 1 patients to €8,924 for Grade 4 patients for 
direct costs and €8,621 for GOLD Grade 1 patients rising to an average of €27,658 for Grade 4 
patients for indirect costs (27). In Italy, average healthcare costs for patients with severe COPD is 
€6700 per patients per year, of which hospitalisations are a substantial proportion (over 60%) (28), 
and in Spain the average health care cost per patient per year with COPD is approximately €2000 
with medicines comprising approximately 40% of costs (29, 30) 
 
The current economic burden of COPD in India is largely unknown (8), although Patel et al (2014) 
calculated direct medical costs were up to Rs. 5876.00 (US$88.23) per patient from admission to 
discharge among hospitalised patients, with the costs of medicines a substantial proportion at over 5 
times hospital charges (31). This is very different to the situation in higher income countries. Naveed 
et al (2016) calculated an average annual total direct cost per patient for COPD of Rs. 5000 (US$ 
75.08) to 25,000 (US$ 375.38), considerably higher than the direct medical costs for asthma at Rs. 
1000–20,000  (US$ 15.02–300.30) (32). A substantial proportion of these costs in India will be out-of-
pocket (8, 33). 
 
The morbidity, mortality and costs associated with COPD are enhanced if patients with COPD face 
both adherence and inhaler use barriers (34-38). As a result, multifactorial approaches that include 
comprehensive health education for COPD patients in all aspects of care should be considered (1). 
As mentioned, effective integrated interventions in ambulatory care, including earlier diagnosis and 
instigating strategies to help prevent disease progression, can reduce the rate of exacerbations, 
hospitalizations and the rising economic burden of COPD (39-43). In the global initiative for chronic 
obstructive lung disease (GOLD) report of 2018, pharmacists are considered as key health care 
professional collaborators assisting in the management of COPD through educational strategies (1). 
Pharmacists can help with medication management strategies as well as assist with addressing 
barriers to the use of, and adherence with, prescribed inhalers. Consequently, community 
pharmacists can potentially, help reduce the morbidity, mortality and costs associated with COPD and 
delay its progression (44-47). 
 
This is particularly important in India given concerns with the number of physicians especially in rural 
areas due to a variety of issues (48-50).  As a result, counselling of COPD patients in terms of 
prevention strategies and inhaler techniques, as well as the use of spirometry for diagnosis, is 
typically limited (51). This is a concern given the high levels of co-payment in India, which can have a 
devastating effect on families (8, 52, 53), as well as the current high burden of COPD in India (2, 6, 
13). Consequently, effective strategies are need to address this. This includes the improved use of 
medicines to reduce subsequent co-payments (22). We and others have shown that structured 
pharmacist-led interventions can improve the care of patients with COPD and help reduce costs (46, 
54-58). This is important with the role of non-physician healthcare professionals growing in India to 
compensate for the lack of physicians (59). Currently, there are over one million pharmacists in India, 
with a clinically oriented Doctor of Pharmacy (PharmD) program introduced in 2008 to help train 
pharmacists to provide patient-related care. This includes patient counselling and therapeutic 
interventions, which should help to improve the care of patients with chronic diseases in India (53). 
There is though limited data regarding the economic impact of pharmacists’ involvement in the 
management of patients with COPD in India, especially with respect to medicine costs.  
 
Consequently, we undertook this study to address this by evaluating the impact of clinical 
pharmacists’ intervention on the costs of medicines for patients with COPD in a randomised trial, 
coupled with the costs of pharmacists’ time, to provide future guidance as India moves towards 
providing universal health care (60). We concentrated on these two direct medical costs initially since 
the costs of medicines currently account for approximately 38% of total healthcare costs in India 
versus approximately 10% of total healthcare costs among developed countries, much of which is out-
of-pocket (33, 53, 61, 62). In addition, as mentioned, costs of medicines for patients with COPD is 
currently appreciably higher than hospital charges (31). 
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2. Patients and Methods 
2.1 Study Design and Subjects 
The study was carried out as part of a larger study evaluating the impact of structured pharmacist-led 
interventions on improving medication adherence in patients with COPD and the subsequent impact 
on their health-related quality of life (44, 46).  
 
An open-label randomized controlled study was conducted at Kasturba Medical College Hospital, 
Manipal, India, which is a tertiary care teaching hospital, over a three-year period. The study subjects 
were selected based on inclusion criteria (confirmed diagnosis of COPD as per GOLD guidelines) and 
their informed consent. Patients were randomized (by sealed envelope method) into two groups, 
which were the intervention group [IG] and the control group [CG], to ensure as far as possible 
matching between the two groups.  
 
2.2 Sample size  
Based on previous published literature (54, 55), we estimated the minimum sample size (based on 
measures of variation) of 100 patients in each group in order to demonstrate minimum clinical 
significance of 5% (power =80%). The target sample size was estimated to be 260 patients (130CG 
and 130 IG) taking into account a 30% potential dropout rate.  
 
2.3 Treatment Costs 
Medicine costs were collected before and after the intervention were based on the data collected from 
case record forms (CRF) and personal interviews. The costs of medicines included the cost of 
glucocorticoids, anticholinergics, antibiotics, methylxanthines and bronchodilators. This excluded any 
medicines that were returned and could be re-used. The cost of medicines used to treat non-
respiratory conditions were also excluded as we wanted to concentrate solely on the cost medicines 
for COPD. 
 
Medicine costs were collected for each patient from the billing system in the hospital. These were 
collated from the hospital pharmacy billing system for each patient for the three data collection time 
points and recorded on their CRF as total combined costs without being broken down into their 
respective components (different inhalers and oral medicines). In addition, during the interviews with 
the patients, information regarding over-the-counter (OTC) medicines and their costs were collected 
as well as the cost of any other medicines purchased from outside hospital to ensure all medicines 
costs were included. Costs were collected for the fiscal year 2012 to 2014 in Indian rupees (INR) and 
inflated to 2017 costs using current Indian inflation rates (63). These were subsequently converted to 
2017 United States Dollars (US$) using an average exchange rate (1 USD = 66.60 INR). The costs 
were grouped into periods of six months for comparative purposes. This was six months prior to the 
documented time, i.e. 6 months before the baseline as well as the six-month period prior to 12 and 24 
months. A six month period was chosen to cover possible monthly fluctuations in inhaler use.  
 
Since the variation in the severity of COPD disease may affect the median estimated direct costs for 
the patient in each group, the cost difference in the median estimated costs between two groups was 
also assessed using the cost ranges in each group via boxplots.     
 
The cost of the clinical pharmacy input was also calculated to provide a more complete picture of 
overall potential cost savings. This was based on an average monthly salary of a clinical pharmacist 
in India in 2017 being approximately 28000 INR (US$420), although this may vary according to their 
qualifications and experience (64). Typically, a clinical pharmacist in India works 8 hours per day for 
25 days in a month, making 200 working hours a month. This corresponds to 140 INR (US$2)/ hour.  
 
As mentioned, no attempt was made to look at the impact of any changes in medicine use on longer 
term costs including future hospitalisations due to exacerbations as the main emphasis was on the 
costs of medicines, the principal cost component (31), much of which will be out-of-pocket (8, 33). 
In addition, we had previously shown that this structured pharmacist-led intervention significantly 
improved medication adherence in COPD patients, which has been shown to decrease the number of 
emergency department visits and and the length of stay in hospitals among patients with chronic 
respiratory diseases (46, 65).  
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2.4 Assessments 
The baseline data for each patient was collected using a custom designed and validated CRF that we 
have previously used and discussed (46). The collected data included demographic measures, 
clinical characteristics, as well as respiratory and non-respiratory medication regimen. Follow up 
assessments were repeated at 12 and 24 months in both the CG and IG groups.  
 
2.5 Structured Pharmacist Intervention 
Patients recruited in the IG were educated by the principal clinical pharmacist (SA). The counselling 
sessions (typically 15-20 minutes) and patient information leaflets (PILs) emphasised the following: (i) 
the importance of medication compliance, (ii) the dose and frequency of prescribed medicines, (iii) the 
need for smoking cessation, (iv) the need for simple exercise, (v) the proper use of prescribed inhaler 
devices and (vi) the need for timely monitoring by the pulmonary medicine department. There were 
five counselling sessions during the 2-year follow up period.  
 
Each patient was followed up for a period of two years, and adherence was re-assessed every six 
months. PILs describing the above techniques had been developed, validated and supplied to 
patients for reinforcing the content delivered through counselling (66). Patients were further contacted 
by telephone each month to enhance medication adherence and timely follow up. During the follow-
up, patients in the IG were further trained regarding the proper use of inhaler devices and motivated 
regarding the need for medication adherence. 
 
The control patients just received normal care in the clinic without any pharmacy counselling and 
follow-up by the clinical pharmacy team. 
 
2.6 Data analysis 
SPSS version 20.0 was used for statistical analyses (data screening, descriptive statistics and 
univariate analysis). A P-value of <0.05 was considered statistically significant.  
 
2.7 Ethical clearance 
Institutional ethical clearance (IEC 88/2012) was obtained prior to the study and the study was 
registered with the Indian clinical trial registry (CTRI/2014/08/004848). 
 
3. Results 
 
3.1 Patient Flow and Baseline characteristics 
Of the 328 COPD patients screened during the study period, 260 were recruited. Of these, 202 
patients completed the follow-up (98 in CG and 104 in IG). The reasons for dropping out, in 
decreasing order of events were: (a) lost to follow up (18 in CG and 11 in IG), (b) death (8 in CG vs 9 
in IG), and (c) withdrawal at different stages of the study (5 in CG vs 3 in IG). Figure 1 indicates the 
number of patients at different stages of the study. 
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The randomisation process ensured the CG and IG groups were matched for baseline socio-
demographic and clinical characteristics (Table 1) including (a) mean age (61.1 ±8.4 vs. 60.6 ±7.9 
years), (b) male gender (94.4 vs 96.9%), (c) duration of COPD (15.3±5.7 vs 14.6 ±6.6 years), (d) 
mean forced expiratory volume (FEV1) % (41.9±14.7 vs 44.4±14.5), (e) average number of medicines 
used (7.2±2.1 vs 6.3±1.7), (f) co-morbidity rate (74% vs 69%), and (g) current smoking status (53.8% 
vs 56.9%). They were also matched in terms of baseline medicines (Figure 2). 
 
As per Kuppuswamy’s socioeconomic classification (67), the largest proportion of patients belonged 
to the upper lower category in both groups (CG = 30.5% vs IG = 29.8%). The ‘smoking score’ (Pack 
years) was estimated to be 21.7 ±12.6 in CG and 23.2 ±11.4 in IG.  The largest proportion of the 
patients belonged to the GOLD III (severe) category (45.4 vs 47.6 %). The socio-economic status of 
patients was based on published classifications (18).  
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Table 1: Baseline characteristics of study population 
 
Characteristics CG IG P-value 
Gender (Male, %)‡ 94.4 96.9 0.08 
Age (Mean±SD)† 61.1±8.4 60.6±7.9 0.67 
         Age Category‡   0.12 
                               40-50 20 15  
                               50-60 32 47  
                               60-70 78 68  
Socioeconomic status (%)‡                                                  0.73 
    Lower 35.8 37.4  
    Upper lower 30.5 29.8  
    Middle 23.7 20.6  
    Upper middle 7.1 6.4  
    Upper  2.9 5.8  
FEV1 % predicted¶ (Mean±SD)† 41.9±14.7 44.4±14.5 0.16 
Severity as per GOLD (%)‡                                                  0.34 
       Mild 12.7 13.8  
       Moderate 21.9 20.1  
       Severe 45.4 47.6  
       Very severe 20.0 18.5  
Pack years (Mean± SD) † 21.7±12.6 23.2±11.4 0.42 
Smoking Status (%)‡                                                  0.24 
      Ex-Smoker 43.1 46.2  
      Current smoker 56.9 53.8  
Duration of COPD(Mean± SD) † 15.3±5.7 14.6±6.6 0.36 
Co morbid conditions (%) ‡ 74 69 0.64 
No. of Medications (Mean±SD) † 7.2±2.1 6.3±1.7 0.68 
NB: IG: Intervention group, CG- Control group, SD- standard deviation, FEV1-Forced expiratory volume in one 
second, COPD-Chronic Obstructive Pulmonary Disease, GOLD- Global Initiative for Chronic Obstructive Lung 
Disease; †Data were analysed by t test; ‡Data were analysed by Chi square; ¶ FEV1 calculated based on 
spirometry. 
 
3.2 Medicine costs in COPD patients 
At baseline, the average medicine costs of the enrolled patients were highly correlated with disease 
severity. Box 1 lists the medicines prescribed/ dispensed in both groups among the COPD patients to 
treat their COPD, with Figure 2 giving a further breakdown showing a similar use of the different 
medicine types between both groups at baseline. These were typically different inhalers (short and 
long acting beta 2 agonists, steroids and anticholinergics). 
 
Box 1 - List of medicines most commonly prescribed/dispensed among the patients with 
COPD 
 
Beta 2 adrenergic agonists (short and long acting inhalers) 
     Salbutamol, Levosalbutamol   
     Salmeterol  
     Formoterol  
Anticholinergics (inhalers) 
     Ipratropium  
Glucocorticoids 
     Prednisolone (oral) 
     Budesonide (inhaler) 
     Fluticasone (inhalers) 
Phosphodiesterase inhibitors (oral) 
     Doxophylline, Theophylline  
     Acebrophylline  
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Figure 2 – Medicines prescribed in each group (CG and IG) as a percentage of total medicines 
prescribed (items) 
 
 
 
Mild COPD cost the least per patient for medicine costs at baseline (CG=US$29.46 vs. IG=US$27.44. 
Predictably, patients with very severe COPD incurred the highest medicine costs initially (CG = 
US$62.00 vs IG = US$63.28) (Table 2).  
 
The cost of medicines decreased significantly after the pharmacist intervention in the IG for all levels 
of severity of COPD. For patients with mild COPD, the average six-monthly medicine costs at 24 
months were US$41.47 for the CG group and US$31.46 per patient for the IG. For those with very 
severe COPD, the medicine costs were US$66.94 for the CG group and US$46.45 per patient for 
those in the IG group. Overall, the structured pharmacist-led intervention saved US$10.01 per patient 
for medicine costs over a six-month period prior to 24 months for those with mild COPD versus 
US$20.49 for those patients with very severe COPD, equating to a reduction ranging from 17.1% 
(moderate) up to 30.6% (very severe) (Table 2).  
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Table 2: Medicine costs median) in COPD patients over a six-month period at baseline and 
prior to 24 months 
 
Severity of COPD 
Baseline (cost 
in US$) 
24 months (cost 
in US$) 
Medicine costs saved 
by a structured 
pharmacist-led 
intervention (US$ and 
%) 
Statistical 
significance of 
the reductions at 
24 months 
CG IG CG IG 
IGa 
(24 months) 
P value (T-test) 
Stage-I (Mild) 29.46 27.44 41.47 31.46 10.01 (-24.1%) P < 0.001 
Stage-II 
(Moderate) 
35.41 38.35 42.28 35.03 7.25 (-17.1%) P < 0.001 
Stage-III (Severe) 53.69 52.00 58.24 43.00 15.24 (-26.2%) P < 0.001 
Stage-IV (Very 
severe) 
62.00 63.28 66.94 46.45 20.49 (-30.6%) P < 0.001 
NB: CG: control group, IG: intervention group, COPD: Chronic Obstructive Pulmonary Disease, US$: US Dollar, a 
Compared to CG (24 months) 
 
3.3 Comparative analysis of medicine costs among COPD patients     
             
The cost differences in estimated medicines costs between the two groups were assessed by using 
the cost ranges in each group as shown in the boxplots.     
 
3.3.1 Estimated median medicine costs among COPD patients at baseline 
The median estimated direct medicine costs at baseline were similar between the CG and IG groups 
(US$52.63 vs 51.73, P = 0.916). The medicine costs ranged from a minimum of US$ 26.84 in the CG 
and US$25.81 in IG to a maximum of US$62.13 (CG) and US$63.33 (IG). Figure 3 shows the boxplot 
of the cost comparison between the CG and IG groups at baseline. 
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Figure 3: Boxplot of medicine cost comparisons between the intervention and control groups at 
baseline (Median (IQR) 
 
 
 
3.3.2 Estimated median medicine costs (USD) among COPD patients at 12 months 
The median estimated medicine cost at 12 months were significantly higher for the CG than the IG 
(US$56.09 vs US$46.79, P < 0.001). The medicine costs ranged from a minimum of US$32.15 in the 
CG and US$ 26.45 in the IG to a maximum of US$ 67.82 (CG) and US$ 60.01 (IG). Figure 4 shows 
the boxplot of cost comparisons between the CG and IG groups at 12 months. 
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Figure 4: Boxplot of medicine cost comparison between the intervention and control groups at 12 
months (median (IQR) 
 
 
 
3.3.3 Estimated median medicine cost (US$) of COPD patients at 24 months 
The median estimated medicine costs at 24 months were significantly higher for the CG than the IG 
group (US$ 57.82 vs US$ 41.29, P < 0.001). The medicine costs ranged from a minimum of US$ 
39.09 in the CG and US$ 29.21 in the IG group to a maximum of US$68.09 (CG) and US$48.98 (IG). 
Overall, median medicine costs were reduced by 28.6% in the IG vs CG groups. Figure 5 shows the 
boxplot of cost comparisons between the CG and IG at 24 months. 
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Figure 5: Boxplot of medicine cost comparison between the intervention and control groups at 24 
months (median (IQR) 
 
 
 
3.4 Costs of clinical pharmacist time 
The time for counselling of each COPD patient was found to be 20 minutes on average during the 5 
sessions of counselling per patient during the study period. Consequently, the estimated average 
counselling time for each patient was 1 hour 40 minutes (over the two years). This equates to 200 
INR (US$3) per COPD patient. The inclusion of these costs reduces potential savings; however, they 
are still substantial (Table 3). 
 
Table 3 – Potential direct medicine cost savings from the pharmacist intervention programme 
  
Severity of COPD 
Median medicine cost 
saved by structured 
pharmacist-led 
intervention (US$) (Table 2) 
Pharmacist 
costs (US$) 
Overall 
savings 
(US$) 
Overall % cost 
reduction from CG 
costs (Table 2) 
Stage-I (Mild) 10.01  3.00 7.01 -16.9% 
Stage-II (Moderate) 7.25 3.00 4.25 -10.1% 
Stage-III (Severe) 15.24 3.00 12.24 -21.0% 
Stage-IV (Very 
severe) 
20.49 3.00 17.49 - 26.1% 
NB: CG: control group, IG: intervention group, COPD: Chronic Obstructive Pulmonary Disease, US$: US Dollars 
 
 
4. Discussion  
 
To the best of our knowledge, we believe this is the first randomised controlled study from India to 
evaluate the impact of a pharmacist-led intervention on the cost of medicines to treat patients with 
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their COPD. The savings can be substantial, reducing six-monthly medicine costs among those with 
very severe COPD by US$20.49 to US$46.45, i.e. by 30.6% (Table 2), with lower savings with milder 
COPD. These savings are still high at US$17.49 (a reduction of 26.1%) when factoring in clinical 
pharmacy time (Table 3), with the percentage reduction at 30.6% for those with very severe disease if 
we had evaluated medicine costs over twelve rather than six months. The findings that the costs of 
medicines increase with disease severity is expected, similar to those of Hilleman and others (27, 31, 
68). These savings in medicines costs are important given the extent of co-payments for medicines 
for patients with COPD in India as well as in other LMICs (8, 33, 52, 53). In India, most COPD 
patients are from rural areas; consequently, the cost of therapy remains a high burden for patients 
and their families. Affordability of medicines is a key issue in LMICs with their costs accounting for up 
to 70% of total healthcare costs, most of which will be out-of-pocket and potentially catastrophic for 
patients and their families if family members become ill (52, 69).  
 
By investing 200 INR (US$3) per COPD patient in pharmacist-led interventions, approximately US$7 
to US$18 can be saved in medicine costs in mild and very severe disease respectively (Table 3), 
greater if we had evaluated medicine costs over twelve rather than six months. Encouragingly, care 
appears not be compromised with these savings. If anything, care appears to be improved with this 
pharmacist-led intervention, with the findings from other parts of this research project showing 
improved adherence to medicines as well as improved HRQOL in patients with COPD following the 
intervention(44, 46). This is encouraging given the extent of COPD in India and its current impact on 
morbidity, mortality and costs (5, 6, 8, 10, 15, 31). 
 
Our study corroborates previous reports that demonstrate the value of pharmacist-driven patient 
educational activities among patients with COPD, reinforcing that medication adherence and inhaler 
technique are very important issues to discuss at every follow up visit with patients to improve their 
care and help reduce overall costs (47, 54, 55, 70). In agreement with our study results (Table 2), 
other authors have also demonstrated that the introduction of self-management plans in COPD 
patients have economic benefits (57, 71). Pharmacist led self-management plans can also minimize 
or help prevent medicine related problems, avoiding unnecessary hospital admissions in patients with 
COPD (47). From previous studies (29, 44-47, 65), it is clear that adherence to medication in patients 
with COPD leads to improved disease control, reducing drug dosages and frequency, the use of 
emergency medicines and hospitalisations. This ultimately reduces costs including medicine costs. In 
contrast, poorly controlled COPD, which is typically associated with failure to use inhaled medications 
correctly, was estimated to increase costs in patients with COPD in Italy by at least €9 billion per year, 
with the costs falling substantially with appropriate inhaler and other care (28, 72). This is not 
surprising as adherence to inhaler therapy is typically low in routine care (73-75). As a result in the 
GOLD guidelines (1), COPD management is described as 10% medication and 90% education, with 
only 17% of patients achieving perfect medication adherence without assistance (76). Consequently, 
we believe based on our findings and those of others, there is a potential role for pharmacists to 
educate patients about importance of medication adherence to manage their COPD when dispensing 
the different inhalers and other prescribed medicines to treat their disease.  This in turn will help to 
stabilize their disease, and decrease overall medicines costs as well as overall costs (including 
pharmacists’ costs).  This is particularly important in LMICs with their high patient co-payments and 
current burden of COPD. 
 
This should be of help to key stakeholder groups in India with pharmacists currently a major 
healthcare work force, with over 1 million in practice in India (53). Pharmacists are ideally placed in 
the healthcare system as they act as a link between patients and physicians, and are often the first 
healthcare professional that patients in LMICs approach with health-related problems (77). They can 
also help review the quality of prescribing including prescribing against agreed national guidance, 
which is currently being under-utilised in India (78-81). In addition, pharmacists can help address 
concerns with generics to reduce co-payments (82) as well as help limit tobacco smoking to reduce 
COPD (83-86) alongside other policies to reduce smoking. Other initiatives include increasing the cost 
of cigarettes and through greater enforcement of legislation prohibiting smoking in public places (22). 
Consequently, we believe that our study endorses expanding pharmacists’ role as an economically 
viable strategy in India as well as improving patient care, and we will be monitoring this in the future. 
This may apply to other LMICs especially those where there is currently high morbidity, mortality and 
costs due to COPD. 
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We are aware of a number of limitations with this study. The major one being that this study was 
conducted in only one centre in India, which could affect the generalisation of study findings to other 
institutions. However, we believe that in view of the robustness of the study design and the fact that 
pharmacy counselling skills are easily transferable, our findings are valid and provide future direction 
to others. We are also aware we focused only on medicine costs in this study. In addition, we did not 
break down the medicine costs into the different drug components (different inhalers and oral 
treatments). However, as mentioned, previous studies in India have shown that medicine costs are a 
substantial part of overall costs of treating patients with COPD with typically low salaries unlike high-
income countries. Medicine costs can account for over 70% of total healthcare costs in LMICs, and in 
India much of this will be out-of-pocket putting considerable strain on families where family members 
become ill especially those in rural areas. Consequently, initiatives to reduce medicine costs whilst 
improving the care of patients with COPD should be welcomed. 
  
5. Conclusion:  
 
In conclusion, we believe our study demonstrates a potentially pivotal role of pharmacist in reducing 
the direct medicine cost in COPD patients through a structured educational intervention. These 
savings can be achieved with minimal costs in terms of pharmacists’ time. Consequently, we believe 
our findings will be of interest to the authorities in India and other LMICs with high morbidity, mortality 
and costs due to COPD. 
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